IntegraGen announced that it presented data on several proprietary microRNA biomarkers during the 2018 European Lung Cancer Conference (ELCC) being held in Geneva, Switzerland. Based on an analysis of liquid biopsy samples from over 500 patients with advanced squamous cell carcinoma of the lung enrolled in the Lux-Lung 8 Phase III Clinical Trial, the data presented demonstrated that the expression of specific microRNAs in the serum can differentiate patient response to afatinib and erlotinib therapy and identify emergence of EGFR-TKI resistance during therapy. Data presented at this year’s ELCC meeting includes: Yann Gaston-Mathe, Paul Fogel, Séverine Martin-Lannerée, et al., Circulating miR-31 as a predictive marker of EGFR TKI treatment efficacy in squamous cell lung cancer (SCC): a sub-analysis of the LUX-Lung 8 trial. Yann Gaston-Mathe, Paul Fogel, Séverine Martin-Lannerée, et al., Circulating microRNAs as novel predictive markers of afatinib efficacy in squamous cell lung cancer (SCC): an exploratory sub-analysis of the LUX-Lung 8 trial.